Do we still need positron emission tomography for early Alzheimer's disease diagnosis?

Brain

Volumn 139, Issue 11, 2016, Pages e60-

  Lewczuk, Piotr ^a,b   Kornhuber, Johannes ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL LABORATORY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZING; GERMANY; HEALTH CARE COST; HUMAN; LETTER; LUMBAR PUNCTURE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN METABOLISM; SHIPPING; BRAIN;

ALZHEIMER DISEASE; BRAIN; EARLY DIAGNOSIS; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84994508491     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww168     Document Type: Letter

References (11)

1. Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 1993; 88: 221-3.
2. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-28.
3. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 2013; 54: 476-90.
4. Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, et al. Comparison of different matrices as potential quality control samples for neurochemical dementia diagnostics. J Alzheimers Dis 2016; 52: 51-64.
5. Lewczuk P, Kornhuber J, Toledo JB, Trojanowski JQ, Knapik-Czajka M, Peters O, et al. Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer's disease in pre-dementia subjects. J Alzheimers Dis 2015; 49: 887.
6. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloidbeta and florbetapir imaging in Alzheimer's disease. Brain 2015; 138(Pt 3): 772-83.
7. Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 2016; 139: 1551-67.
8. Palmqvist S, Mattsson N, Hansson O; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain 2016; 126: 1226-36.
9. Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Alzheimer's Disease Neuroimaging Initiative, Minthon L, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 2015; 85: 1240-9.
10. Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. J Alzheimers Dis 2014; 42 (Suppl 4): S421-9.
11. Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis 2011; 25: 739-45.